Millendo Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Millendo Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11198
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Millendo Therapeutics Inc (Millendo Therapeutics), formerly Atterocor Inc is a drug development company that develops treatments for endocrine diseases including vasomotor. The company provides development of innovative treatments for orphan endocrine disorders such as adrenocortical carcinoma caused by hormone abnormalities. Its pipeline products include ATR-101 and MLE4901. Millendo Therapeutics’ MLE4901 product is used for the treatment of polycystic ovary syndrome and MLE4901 is a neurokinin 3 receptor antagonist that helps decrease gonadotropin releasing hormone hyperpulsatility and luteinizing hormone pulse frequency. The company’s ATR-101 is used to treat ACC congenital adrenal hyperplasia and endogenous cushing’s syndrome. It also provides treatments for endocrine diseases caused by hormone dysregulation of medications exist. Millendo Therapeutics is headquartered in Ann Arbor, Michigan, the US.

Millendo Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 10
Millendo Therapeutics Secures USD16 Million in Series A Venture Funding 12
Atterocor Raises US$16 Million In Series A Financing 13
Atterocor Raises US$0.3 Million In Venture Financing 14
Merger 15
OvaScience to Merge with Millendo Therapeutics 15
Licensing Agreements 17
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 17
Acquisition 18
Millendo Therapeutics Acquires Alize Pharma 18
Millendo Therapeutics Inc – Key Competitors 19
Millendo Therapeutics Inc – Key Employees 20
Millendo Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Corporate Communications 22
Nov 14, 2018: Millendo Therapeutics names Louis Arcudi III as Chief Financial Officer and Michael Yeh as Vice President of Medical Affairs 22
Sep 25, 2018: Millendo Therapeutics names Habib Dable as Board Director 23
Jun 28, 2018: Millendo Therapeutics Names Dr. Ryan Zeidan as Senior Vice President, Development and Strengthens Leadership Team with Key Promotions 24
Apr 11, 2017: Millendo Therapeutics Appoints Mary Lynne Hedley, Ph.D. and Carole Nuechterlein, J.D. to Board of Directors 25
Clinical Trials 26
Sep 17, 2018: Millendo Therapeutics starts Phase llb trial of nevanimibe for CAH 26
Mar 07, 2018: Millendo Therapeutics Announces Data Presentation for Nevanimibe at ENDO 2018 27
Nov 08, 2017: Millendo Therapeutics Announces Positive Topline Phase 2 Results of ATR-101 in Classic Congenital Adrenal Hyperplasia 28
Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing’s Syndrome 29
Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for ATR-101 at ENDO 2017 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Millendo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Millendo Therapeutics Raises USD62 Million in Series B Venture Financing 10
Millendo Therapeutics Secures USD16 Million in Series A Venture Funding 12
Atterocor Raises US$16 Million In Series A Financing 13
Atterocor Raises US$0.3 Million In Venture Financing 14
OvaScience to Merge with Millendo Therapeutics 15
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 17
Millendo Therapeutics Acquires Alize Pharma 18
Millendo Therapeutics Inc, Key Competitors 19
Millendo Therapeutics Inc, Key Employees 20

List of Figures
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Millendo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Millendo Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Victorian WorkCover Authority:企業の戦略的SWOT分析
    Victorian WorkCover Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Chiesi USA Inc:企業の戦略的SWOT分析
    Chiesi USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Compagnie Plastic Omnium SA (POM):企業の財務・戦略的SWOT分析
    Compagnie Plastic Omnium SA (POM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析
    RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • DreamWorks Animation LLC:企業の戦略的SWOT分析
    DreamWorks Animation LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Standard Life plc:企業のM&A・事業提携・投資動向
    Standard Life plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Standard Life plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • NTT Data Corporation:企業のM&A・事業提携・投資動向
    NTT Data Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NTT Data Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • ICBC Standard Bank Plc:企業の戦略・SWOT・財務情報
    ICBC Standard Bank Plc - Strategy, SWOT and Corporate Finance Report Summary ICBC Standard Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Eydo Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eydo Pharma SAS (Eydo Pharma) develops anti-bacterial medicines from essential oils and natural plant molecules for the treatment of infections caused by resistant bacteria. The company developed a pipeline of compounds and formulations such as EP1012, EP1010, EP1011, EP1014, EP1015, EP1020 …
  • The Interpublic Group of Companies, Inc. (IPG):企業の財務・戦略的SWOT分析
    The Interpublic Group of Companies, Inc. (IPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Mitsui Fudosan Co Ltd (8801):企業の財務・戦略的SWOT分析
    Mitsui Fudosan Co Ltd (8801) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Penn National Gaming Inc:企業の戦略・SWOT・財務情報
    Penn National Gaming Inc - Strategy, SWOT and Corporate Finance Report Summary Penn National Gaming Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • POSCO:企業のM&A・事業提携・投資動向
    POSCO - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's POSCO Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisin …
  • Aeon Co., Ltd.:企業の戦略・SWOT・財務情報
    Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Pareteum Corp (TEUM):企業の財務・戦略的SWOT分析
    Pareteum Corp (TEUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Shinva Medical Instrument Co Ltd (600587)-医療機器分野:企業M&A・提携分析
    Summary Shinva Medical Instrument Co., Ltd. (Shinva Medical) manufactures and markets medical instruments and environmental protection equipment for various healthcare markets. The company’s products portfolio includes sterilizers, radiotherapy equipment, digital diagnosis equipment, surgical instru …
  • TESARO Inc (TSRO):製薬・医療:M&Aディール及び事業提携情報
    Summary TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The co …
  • Casio Computer Co., Ltd.:企業の戦略・SWOT・財務分析
    Casio Computer Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Casio Computer Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Cadila Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Cadila Pharmaceuticals Ltd (Cadila Pharmaceuticals) is a pharmaceutical company that develops, manufactures and distributes pharmaceutical products. The company's products include active pharmaceutical ingredients (API) and pharmaceutical formulations. Its business includes contract research …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆